Circulation:APOL1风险等位基因与心血管疾病的相关性

2019-09-23 MedSci MedSci原创

约13%的黑种人携带2个拷贝的载脂蛋白L1(APOL1)风险等位基因G1或G2,与慢性肾病风险增加1.5-2.5倍相关。关于APOL1风险等位基因与心血管疾病(CVD)之间是否存在独立于APOL1对肾脏疾病的影响之外的关联,一直存在相互矛盾的报道。现研究人员对APOL1 G1/G2等位基因与黑人冠状动脉疾病、外周血管病和卒中的相关性进行评估。研究人员对电子健康病例进行回顾性分析。主要暴露是APOL

约13%的黑种人携带2个拷贝的载脂蛋白L1(APOL1)风险等位基因G1或G2,与慢性肾病风险增加1.5-2.5倍相关。关于APOL1风险等位基因与心血管疾病(CVD)之间是否存在独立于APOL1对肾脏疾病的影响之外的关联,一直存在相互矛盾的报道。现研究人员对APOL1 G1/G2等位基因与黑人冠状动脉疾病、外周血管病和卒中的相关性进行评估。

研究人员对电子健康病例进行回顾性分析。主要暴露是APOL1风险等位基因状态。主要结点是在随访的12.5年内无慢性肾病的个体冠状动脉疾病的发病率。

共纳入30903位个体,其中3941位(13%)携带2个APOL1风险等位基因高危基因型。具有2个风险等位基因且起始时肾功能正常的个体罹患冠状动脉疾病的风险稍高于无风险等位基因的个体(风险比[HR] 1.11[95% CI 1.01-1.21],p=0.039)。与此类似,APOL1风险等位基因的携带状态与卒中和外周动脉疾病发病率也存在中度的相关性(HR 分别是1.20和1.15)。当心血管和肾脏预后都被建模时,APOL1与肾脏疾病密切相关,但与CVD预后没有显著相关性。

APOL1风险突变与CVD具有中度相关性,这种相关性可能是由已知的与慢性肾病相关的APOL1介导的。

原始出处:

本文系梅斯医学(MedSci)原创编译,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837727, encodeId=7d1d183e727c6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 17 12:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484156, encodeId=38ac1484156f6, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498634, encodeId=6a7914986340c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373107, encodeId=058a3e31072a, content=实用性很强, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90905194201, createdName=14722d12m20暂无昵称, createdTime=Mon Sep 23 21:26:28 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373106, encodeId=84eb3e3106b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Sep 23 20:51:01 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837727, encodeId=7d1d183e727c6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 17 12:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484156, encodeId=38ac1484156f6, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498634, encodeId=6a7914986340c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373107, encodeId=058a3e31072a, content=实用性很强, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90905194201, createdName=14722d12m20暂无昵称, createdTime=Mon Sep 23 21:26:28 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373106, encodeId=84eb3e3106b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Sep 23 20:51:01 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837727, encodeId=7d1d183e727c6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 17 12:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484156, encodeId=38ac1484156f6, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498634, encodeId=6a7914986340c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373107, encodeId=058a3e31072a, content=实用性很强, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90905194201, createdName=14722d12m20暂无昵称, createdTime=Mon Sep 23 21:26:28 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373106, encodeId=84eb3e3106b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Sep 23 20:51:01 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837727, encodeId=7d1d183e727c6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 17 12:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484156, encodeId=38ac1484156f6, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498634, encodeId=6a7914986340c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373107, encodeId=058a3e31072a, content=实用性很强, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90905194201, createdName=14722d12m20暂无昵称, createdTime=Mon Sep 23 21:26:28 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373106, encodeId=84eb3e3106b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Sep 23 20:51:01 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
    2019-09-23 14722d12m20暂无昵称

    实用性很强

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1837727, encodeId=7d1d183e727c6, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Mon Aug 17 12:40:00 CST 2020, time=2020-08-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1484156, encodeId=38ac1484156f6, content=<a href='/topic/show?id=d2fbe588905' target=_blank style='color:#2F92EE;'>#等位基因#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=75889, encryptionId=d2fbe588905, topicName=等位基因)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=68e17955541, createdName=luckyshitiancai_42705686, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1498634, encodeId=6a7914986340c, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Wed Sep 25 11:40:00 CST 2019, time=2019-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373107, encodeId=058a3e31072a, content=实用性很强, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90905194201, createdName=14722d12m20暂无昵称, createdTime=Mon Sep 23 21:26:28 CST 2019, time=2019-09-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=373106, encodeId=84eb3e3106b8, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=82311653708, createdName=医者仁心5538, createdTime=Mon Sep 23 20:51:01 CST 2019, time=2019-09-23, status=1, ipAttribution=)]
    2019-09-23 医者仁心5538

    学习了

    0

相关资讯

ATVB:APOL1风险变异与心血管疾病!

由此可见,在高血压归因于慢性肾脏病的黑人中,APOL1的风险变异并不与心血管疾病的整体风险相关,虽然心血管死亡的一些信号较为明显。

NEJM:APOL1遗传变异与慢性肾病进展相关(AASK研究和CRIC研究)

在美国有大量的慢性肾病患者,与白人相比,黑人更容易转化成终末期肾病。为了研究不同民族人群慢性肾病的差异,全球320家单位发起了两个大型研究---AASK 研究和 CRIC研究。在这两个研究中,AASK(美国非裔慢性肾病和高血压研究)中,评估了693位患者慢性肾病合并高血压的黑人患者。在慢性肾衰队列研究(CRIC)研究中,评估了2955位患有慢性肾病的白人与黑人,其中46%伴有糖尿病。按照载脂蛋白1